Illumina To Webcast Upcoming Investor Conference
Werte in diesem Artikel
SAN DIEGO, Dec. 4, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference:
- 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2024
Presentation at 9:00am Pacific Time (12:00pm Eastern Time) immediately followed by a Q&A Session to begin at approximately 9:20am Pacific Time (12:20pm Eastern Time)
The webcast can be accessed through the Investor Info section of Illumina's website at investor.illumina.com. A replay will be posted on Illumina's website after the event and will be available for at least 30 days following.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Investors:
Salli Schwartz
+1.858.291.6421
ir@illumina.com
Media:
Bonny Fowler
+1.740.641.5579
pr@illumina.com
View original content:https://www.prnewswire.com/news-releases/illumina-to-webcast-upcoming-investor-conference-302323094.html
SOURCE Illumina, Inc.
Ausgewählte Hebelprodukte auf Illumina
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Illumina
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Illumina Inc.
Analysen zu Illumina Inc.
Datum | Rating | Analyst | |
---|---|---|---|
30.07.2019 | Illumina Hold | Canaccord Adams | |
30.05.2019 | Illumina Outperform | Wolfe Research | |
09.10.2018 | Illumina Neutral | UBS AG | |
31.07.2018 | Illumina Buy | Canaccord Adams | |
31.01.2018 | Illumina Overweight | First Analysis Securities |
Datum | Rating | Analyst | |
---|---|---|---|
30.05.2019 | Illumina Outperform | Wolfe Research | |
31.07.2018 | Illumina Buy | Canaccord Adams | |
31.01.2018 | Illumina Overweight | First Analysis Securities | |
25.10.2017 | Illumina Outperform | Robert W. Baird & Co. Incorporated | |
23.10.2017 | Illumina Buy | Deutsche Bank AG |
Datum | Rating | Analyst | |
---|---|---|---|
30.07.2019 | Illumina Hold | Canaccord Adams | |
09.10.2018 | Illumina Neutral | UBS AG | |
05.01.2018 | Illumina Neutral | BTIG Research | |
02.08.2017 | Illumina Equal-Weight | First Analysis Securities | |
26.04.2017 | Illumina Neutral | Cantor Fitzgerald |
Datum | Rating | Analyst | |
---|---|---|---|
02.11.2016 | Illumina Underweight | First Analysis Securities |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Illumina Inc. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen